ReproCELL is going to continue challenging the new horizon of the ES/iPS cell business as a pioneering company
ReproCELL is a biotech company that was established in 2003 on the basis of technologies developed by Professor Nakatsuji (who had established the first human ES cells in Japan in that year) at Kyoto University and Professor Nakauchi at Tokyo University. The first human ES cells were established at Wisconsin University in 1998, and the first human iPS cells were established at Kyoto University in 2007. Human ES/iPS cell research is still in its early stages, but it is expected to lead to the next generation of life science businesses such as regenerative medicine, tailor-made medicine, and drug development support.
ReproCELL has been playing a pivotal and pioneering role in the ES/iPS cell business by starting to commercialize culture media for human ES/iPS cells in 2005, the world’s first cardiomyocytes derived from human iPS cells in 2009, and the world’s first neurons derived from human iPS cells in 2010. We will continue expanding our business in the field, including the development of culture reagents, stem cell-based drug development support technologies, and tailor-made medicine.
ReproCELL’s company policies are “customer centeredness,” “faith and trust,” and “a frontier spirit.” We believe that the company can exist only by providing value to customers and contributing to society. Toward this purpose, ReproCELL places emphasis on faithfully and bravely taking up new challenges. Through our business, we will contribute to the health and happiness of people worldwide.
Chief Executive Officer
—– ReproCELL Board of Directors Biographies —–
Chikafumi Yokoyama, Ph.D. – Chief Executive Officer
Dr. Yokoyama joined ReproCELL Inc. in 2004 as a general manager of the business development division and became Chief Executive Officer in 2005. He has been responsible for new product management, alliance, and fund raising. He also participated in establishing a Stem Cell and Drug Discovery Institute in which human ES cell research is carried out for the purpose of drug discovery and toxicity testing applications. From 1996 to 2004, Dr Yokoyama worked for McKinsey and Company Inc. as a management consultant and then for Sumitomo 3M, a subsidiary of 3M, as an R&D leader. He received his Ph.D. in chemistry from Tokyo University in 1996.
Daisuke Usui – Director, CFO
NOF Corporation HOYA Corporation Reinnervate Limited CEO（current occupation）
Yoshiyuki Yamakawa – Director
Mr. Yamakawa has been a non-executive director of ReproCELL since 2008. He is the CEO of HIBIKI Partners, a consulting company, and a BOD member of some listed companies. Having graduated from Waseda University in economics, he started his career as a venture capitalist at Nippon Life Insurance. After experiencing directorship of corporate planning at Innotech Corporation, Mr. Yamakawa joined Sosei Co. Ltd. in 2001 and succeeded in its IPO and M&A as a representative executive officer and CFO.
———————– ReproCELL Group CEO ———————–
ReproCELL USA Inc. CEO
Rama Modali, CEO
NIH（National Institutes of Health） National Cancer Institute BioServe Biotechnologies, Ltd. CEO（current occupation） ReproCELL USA Inc. CEO
ReproCELL Europe Ltd. CEO
David Bunton, CEO
Glasgow Caledonian University Biopta Limited CEO（current occupation） ReproCELL Europe Ltd. CEO